Measuring malaria transmission after drug treatment

Submission date	Recruitment status No longer recruiting	Prospectively registered	
31/01/2005		[] Protocol	
Registration date	Overall study status	Statistical analysis plan	
22/07/2005	Completed	[X] Results	
Last Edited 04/02/2016	Condition category Infections and Infestations	Individual participant data	

Plain English summary of protocol

Background and study aims

Malaria is a serious tropical disease spread by mosquitoes. Previous studies monitoring the success of drug treatment in curing malaria in African children had found that drugs differed in whether the cured children were prevented from passing on malaria to mosquitoes. With the new generation of combination drugs becoming widely available in the early 2000s we sought to compare these with the older drugs, and to test whether these were more effective at not only curing the disease, but in preventing further mosquito infections.

Who can participate?

Children under 12 years of age who were brought to the Farafenni hospital, in The Gambia, for malaria treatment.

What does the study involve?

The children are randomly allocated to one of the study medications, and sent home with all the drugs they would need. Our health worker team then visits each child at home (by motorbike) on subsequent days to assist with the continuing treatment, and to monitor the cure by taking small finger-prick blood samples to test for persisting parasites. Seven days after treatment the children are brought in to the study clinic and lab for a thorough check, and those with any potentially infectious parasites in their blood after checking under the microscope are asked to give an additional blood sample. This sample is then used to experimentally feed mosquitoes to check whether this child is still potentially infectious to the insects which spread malaria.

What are the possible benefits and risks of participating? Not provided at time of registration

Where is the study run from? Farafenni hospital in The Gambia

When is the study starting and how long is it expected to run for? January 2000 to December 2003

Who is funding the study? The Wellcome Trust and MRC Laboratories (UK)

Who is the main contact? Dr Colin Sutherland colin.sutherland@lshtm.ac.uk

Contact information

Type(s) Scientific

Contact name Dr Colin Sutherland

Contact details London School of Hygiene & Tropical Medicine Keppel St London United Kingdom WC1E 7HT +44 (0)20 7927 2338 colin.sutherland@lshtm.ac.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers 061910

Study information

Scientific Title

The impact of anti-malarial treatment upon the development and persistence of Plasmodium falciparum gametocytes in vitro and in vivo

Study objectives

That use of artemisinin combination chemotherapy for treating uncomplicated falciparum malaria in children will reduce transmissibility of malaria to mosquitoes, compared to other combinations or to monotherapies.

Ethics approval required Old ethics approval format

Ethics approval(s)

1. LSHTM Ethics Committee, 05/09/2000, ref: 708

2. Joint Gambia Government/MRC Laboratories Ethics Committee, 06/08/2000, ref: SCC/EC 838 /798. Approved annually on 20/09/2001 (ref: SCC/EC 887/844) and 14/08/2002 (ref: SCC/EC 910)

Study design Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Other

Study type(s) Treatment

Participant information sheet

Health condition(s) or problem(s) studied Malaria

Interventions

Combination antimalarial therapy versus established monotherapy. Single-blind open-label randomised controlled trial run over three consecutive transmission seasons in Farafenni, The Gambia.

Intervention Type

Drug

Phase Not Applicable

Drug/device/biological/vaccine name(s)

Artemisinin combination chemotherapy

Primary outcome measure

Major endpoints were:

1. Post-treatment gametocyte carriage over 28 days

2. Infectiousness to mosquitoes of children carrying gametocytes seven days after treatment

Secondary outcome measures

Minor endpoints were: 1. Clinical and parasitological drug efficacy over 28 days of follow-up

Overall study start date

01/01/2000

Completion date

31/12/2003

Eligibility

Key inclusion criteria

1. Children one to ten years of age (either sex) attending Farafenni Health Centre, The Gambia, from September to December in each of 2000, 2001 and 2002

2. Children with a temperature more than 37.5°C, or a history of fever

3. Blood-film positive for P. falciparum at a density greater than 500 parasites per ml

4. Signed informed consent was obtained

Participant type(s)

Patient

Age group Child

Lower age limit 1 Years

Upper age limit

10 Years

Sex Both

Target number of participants 600

Key exclusion criteria

- 1. An inability to take drugs orally
- 2. Treatment with antimalarial chemotherapy within the past two weeks
- 3. Carriage of circulating gametocytes at presentation
- 4. Any evidence of chronic disease or acute infection other than malaria
- 5. Domicile outside the study area (approximately 10 km radius)
- 6. Any signs or symptoms of severe malaria:
- 6.1. Severe anaemia (peripheral blood Packed Cell Volume [PCV] less than 20%)
- 6.2. Hyper-parasitaemia (more than 250,000 per ml peripheral blood)

6.3. Respiratory distress (respiratory rate more than 40 with two of the following: nasal flaring, intercostal indrawing, subcostal recession or grunting)

6.4. Repeated generalised convulsions (three or more per 24 hours or two witnessed seizures in 24 hours)

- 6.5. Haemoglobinuria (dark red/black urine)
- 6.6. Jaundice
- 6.7. Prostration
- 6.8. Circulatory collapse

Date of first enrolment

01/01/2000

Date of final enrolment 31/12/2003

Locations

Countries of recruitment England

Gambia

United Kingdom

Study participating centre London School of Hygiene & Tropical Medicine London United Kingdom WC1E 7HT

Sponsor information

Organisation London School of Hygiene and Tropical Medicine (UK)

Sponsor details Research Grants and Contracts Office Keppel Street

London England United Kingdom WC1E 7HT +44 (0)20 7827 2678 Penny.Ireland@lshtm.ac.uk

Sponsor type University/education

Website http://www.lshtm.ac.uk

ROR https://ror.org/00a0jsq62

Funder(s)

Funder type Charity

Funder Name The Wellcome Trust (UK) (grant ref: 061910)

Funder Name MRC Laboratories (The Gambia) - Scientific Coordinating Committee (Projects: 838, 887 and 910)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study	outpu	ts
-------	-------	----

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<u>Results article</u>	results	01/12/2002		Yes	Νο
<u>Results article</u>	results	01/07/2003		Yes	No
<u>Results article</u>	results	01/01/2004		Yes	No
<u>Results article</u>	results	01/10/2004		Yes	No
<u>Results article</u>	results	28/05/2008		Yes	No